DC

DAVID COOLING

GENENTECH, INC · WASHINGTON, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
3 agencies contacted
Activity
filings by quarter
Works on

Background

Career
WASHINGTON, DC
2024 - present

Specific issues

Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
Pharmacy · 2024 Q4
Issues related to FDA and HHS program funding for the FY24 Labor, HHS, Education and Related Agencies, and FY24 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicines during the COVID-19 public health emergency Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance. Deficit reduction, reconciliation
Budget/Appropriations · 2024 Q4
Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI
Medicare/Medicaid · 2024 Q4
Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to novel coronavirus and COVID-19 research and product development Issues related to drug development including PDUFA and Cures 2.0
Medical/Disease Research/Clinical Labs · 2024 Q4
Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines during the COVID-19 public health emergency Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening
Health Issues · 2024 Q4

Clients

2024 · 4 filings
$██,███ / qtrUnlock

Filing history

2024 Q4
GENENTECH INC
Q4lda.gov →
2024 Q3
GENENTECH INC
Q3lda.gov →
2024 Q2
GENENTECH INC
Q2lda.gov →
2024 Q1
GENENTECH INC
Q1lda.gov →
Showing recent filings · full history on lda.gov